Variables | Levels | OR | 95% CI lower bounds | 95% CI upper bounds | p value |
Age at diagnosis | As one year increase | 0.975 | 0.961 | 0.990 | 0.001 |
Year of diagnosis | 2011 vs 2010 | 0.971 | 0.700 | 1.347 | <0.001 |
2012 vs 2010 | 1.108 | 0.800 | 1.535 | ||
2013 vs 2010 | 1.205 | 0.885 | 1.641 | ||
2014 vs 2010 | 1.713 | 1.271 | 2.308 | ||
Family history (77 unknown) | Yes vs no | 1.198 | 0.985 | 1.458 | 0.071 |
Live children | Yes vs no | 1.131 | 0.909 | 1.408 | 0.271 |
Histology | Lobular no ductal vs ductal no lobular | 1.202 | 0.884 | 1.636 | 0.019 |
Lobular and ductal vs ductal no lobular | 0.983 | 0.663 | 1.457 | ||
Inflammatory vs ductal no lobular | 1.420 | 0.383 | 5.268 | ||
Other vs ductal no lobular | 0.234 | 0.095 | 0.579 | ||
Grade (219 unknown) | G2 vs G1 | 2.988 | 1.674 | 5.331 | <0.001 |
G3 vs G1 | 3.407 | 1.954 | 5.940 | ||
LN pos exact (3 unknown) | Yes vs no | 1.894 | 1.560 | 2.300 | <0.001 |
Stage (210 unknown) | II vs I | 1.477 | 1.176 | 1.856 | <0.001 |
III vs I | 2.859 | 2.153 | 3.798 | ||
Chemotherapy | Yes vs no | 1.516 | 1.232 | 1.865 | <0.001 |
HER-2 targeted | Trastuzumab vs none | 0.892 | 0.655 | 1.214 | <0.001 |
Trastuzumab+other vs none | 2.276 | 1.502 | 3.449 |
The OR is modeled for ovarian suppression (OS)=yes. OR>1 means more likely to get OS; OR<1 less likely to get OS. Unknown=number of patients in analysis who did not have documentation for this variable.
Bold p values represent p values of significance.
HER-2, human epidermal growth factor receptor 2; LN, lymph node; OS, ovarian suppression.